A detailed history of Segall Bryant & Hamill, LLC transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 52,390 shares of TGTX stock, worth $1.53 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
52,390
Holding current value
$1.53 Million
% of portfolio
0.02%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$17.21 - $25.28 $901,631 - $1.32 Million
52,390 New
52,390 $1.23 Million
Q2 2021

Aug 12, 2021

SELL
$32.5 - $48.96 $162,500 - $244,800
-5,000 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$25.27 - $54.9 $126,350 - $274,500
5,000 New
5,000 $260,000
Q1 2018

May 16, 2018

SELL
$8.7 - $16.8 $531,500 - $1.03 Million
-61,092 Closed
0 $0
Q4 2017

Feb 15, 2018

BUY
$7.35 - $12.3 $55,125 - $92,250
7,500 Added 13.99%
61,092 $0
Q3 2017

Nov 14, 2017

BUY
$10.0 - $12.7 $535,920 - $680,618
53,592
53,592 $0

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.23B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Segall Bryant & Hamill, LLC Portfolio

Follow Segall Bryant & Hamill, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Segall Bryant & Hamill, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Segall Bryant & Hamill, LLC with notifications on news.